Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. held its 2026 Annual Meeting of Stockholders, with 50,381,309 common shares represented in person or by proxy, constituting a quorum. Stockholders voted on the election of four Class III directors, ratification of the auditor, and an advisory say‑on‑pay proposal.
All four Class III director nominees were elected, including Geno Germano with 44,963,163 votes for and 1,524,142 withheld, and Troy Ignelzi with 32,813,495 votes for and 13,673,810 withheld. Deloitte & Touche LLP was ratified as independent registered public accounting firm with 49,385,510 votes for and 830,697 against.
Stockholders also approved, on a non‑binding, advisory basis, the compensation of the company’s named executive officers, with 33,249,862 votes for, 13,042,898 against, 194,545 abstentions, and 3,894,004 broker non‑votes.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice proposing the sale of Common stock totaling 45,481 shares. The filing lists restricted stock vesting events of 24,521 shares on 09/30/2024 and 20,960 shares on 04/14/2026.
Harmony Biosciences reported a strong start to 2026 with Q1 net product revenue of $215.4 million, up 17% from $184.7 million a year earlier, driven by continued demand for WAKIX in the U.S. narcolepsy market of about 80,000 diagnosed patients.
Despite higher revenue, net income declined to $32.5 million (diluted EPS $0.55) from $45.6 million ($0.78), which the company attributes entirely to licensing agreements signed in Q1 2026. Operating expenses nearly doubled in R&D as Harmony invested in lifecycle extensions and pipeline assets.
The company ended March 31, 2026 with $870.5 million in cash, cash equivalents and investments, only modestly below year-end levels after up-front license and ANDA settlement payments. Harmony reiterated 2026 WAKIX net revenue guidance of $1.0–$1.04 billion, and highlighted progress on pitolisant GR, pitolisant HD, BP-205 and business development to support long-term growth.
Harmony Biosciences Holdings, Inc. reported continued profitability for the quarter ended March 31, 2026. Net product revenue rose to $215.4 million from $184.7 million a year earlier, driven by growth of WAKIX in narcolepsy.
Higher research and development spending, including $32.0 million of acquired in-process R&D and new license upfronts, reduced net income to $32.5 million from $45.6 million. Diluted earnings per share were $0.55 versus $0.78 in the prior-year period.
Harmony ended the quarter with strong liquidity, holding $589.4 million in cash and cash equivalents and $281.1 million in short- and long-term investments, and a $160.0 million term loan outstanding. Management believes current cash, investments and cash flows will fund operations and planned investing activities for at least the next twelve months.
Harmony Biosciences Holdings, Inc. announced a chief financial officer transition, with Sandip Kapadia stepping down and Glenn Reicin appointed CFO effective April 14, 2026. Kapadia will receive severance under a Separation Agreement consistent with his employment and award agreements, in exchange for a release of claims and ongoing covenants.
Reicin’s Employment Agreement provides a $500,000 annual base salary, a target annual bonus equal to 50% of salary, and a stock option grant with a grant date fair value of $3,000,000, vesting over four years. In a concurrent press release, Harmony reiterated its 2026 net product revenue guidance for WAKIX of $1.0 to $1.04 billion.
Harmony Biosciences Holdings, Inc. reported that Chief Commercial Officer Adam H. Zaeske exercised restricted stock units into common stock and had shares withheld for taxes. On April 7, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a stated price of $0.00 per share, reflecting a stock-based compensation event rather than a market purchase.
To cover required income tax withholdings tied to the RSU vesting, 3,173 shares of common stock were disposed of at $27.62 per share through issuer withholding, leaving Zaeske with 4,327 shares of common stock held directly after these transactions. The RSU award is scheduled to vest in four equal annual installments beginning on April 7, 2026, contingent on continued service.
Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock. The options have an exercise price of $27.74 per share and expire on April 2, 2036.
According to the grant terms, 25% of the underlying shares vest on April 2, 2027, with the remaining options vesting on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with the company.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi reported receiving a stock option grant for 17,710 shares of common stock. The option has an exercise price of $27.74 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market trade.
The option will vest in 36 equal monthly installments beginning on May 2, 2026, meaning the right to exercise the option will phase in gradually over three years.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing lists him as a director of the company but shows no reported transactions or specific share holdings at this time.